HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

SPECIFIC FEATURES OF THERAPY AND PREVENTION OF ONYCHOMYCOSIS TREATED WITH THE NAIL LACQUER AMOROLFINE

Download full text PDF
Issue: 
7
Year: 
2017

E. Kasikhina, Candidate of Medical Sciences Central State Medical Academy, Presidential Administration of the Russian Federation, Moscow

The paper gives the data of an investigation of the efficacy of the nail lacquer (amorolfine 5% – Exorolfinlac) in the treatment and prevention of onychomycosis. It presents an algorithm to choose a topical agent with regard to the etiology and clinical features of onychomycosis. The important advantage of Exorolfinlac is that the agent can be used for the primary and secondary prevention of onychomycosis.

Keywords: 
dermatology
onychomycosis
topical therapy
amorolfine (Exorolfinlac)
clinical trials
prevention of onychomycosis



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Hay R. Literature review. Onychomycosis // J. Eur. Acad. Dermatol. Venereol. – 2005; 19: 1–7.
  2. Nenoff P., Ginter-Hanselmayer G., Tietz H. Fungal nail infections—an update: Part 1. Prevalence, epidemiology, predisposing conditions, and differential diagnosis // Hautarzt. – 2012; 63: 30–8.
  3. Havlickova A., Czaika V., Friedrich M. Epidemiological trends in skin mycoses worldwide // Mycoses. – 2008; 51 (4): 2–15.
  4. Seebacher C., Brasch J., Abeck D. et al. Onychomycosis // Mycoses. – 2007; 50: 321–7.
  5. Del Rosso J. The Role of Topical Antifungal Therapy for Onychomycosis and the Emergence of Newer Agents // J. Clin. Aesthet. Dermatol. – 2014; 7 (7): 10–8.
  6. Iorizzo M., Piraccini B., Tosti A. Today’s treatment options for onychomycosis // J. Dtsch. Dermatol. Ges. – 2010; 8: 875–9.
  7. Baraldi A., Jones S., Guesne S. et al. Human nail plate modifications induced by onychomycosis: implications for topical therapy // Pharm. Res. – 2015; 32: 1626–33.
  8. McAuley W., Jones S. An investigation of how fungal infection influences drug penetration through onychomycosis patient’s nail plates // Eur. J. Pharm. Biopharm. – 2016; 102: 178–84.
  9. Shivakumar H., Juluri A., Desai B. et al. Ungual and transungual drug delivery // Drug Dev. Ind. Pharm. – 2012; 38: 901–11.
  10. Thatai P., Tiwary A., Sapra B. Progressive development in experimental models of transungual drug delivery of anti-fungal agents // Int. J. Cosmet. Sci. – 2015: 1–12.
  11. Baran R., de Berker D., Holzberg M. et al. Diseases of the nails and their management. 4th ed. / Oxford: Wiley-Blackwell, 2012; r. 237.
  12. Dominicus R., Weider C., Tate H. et al. Open-label study of the efficacy and safety of topical treatment with TDT 067 (terbinafine in Transfersome) in patients with onychomycosis // Br. J. Derm. – 2012; 166: 1357–80.
  13. Marty J. Amorolfine nail lacquer: a novel formulation // J. Eur. Acad. Dermatol. Venereol. – 1995; 5: 17–21.
  14. Favre B., Hofbauer B., Hildering, K. et al. Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay // J. Clin. Microbiol. – 2003; 41: 4817–9.
  15. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly // Clin. Exp. Dermatol. – 1992; 17: 41–3.
  16. Reinel D., Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly // Clin. Exp. Dermatol. – 1992; 17: 44–9.
  17. Zaug M., Bergstraesser M. Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview) // Clin. Exp. Dermatol. – 1992; 17: 61–70.
  18. Sigurgeirsson B., Olafsson J. et al. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years // J. Eur. Acad. Dermatol. Venereol. – 2010; 24: 910–5.